Publication: Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer
Open/View Files
Date
2014
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Raval, Mihir, Dinesh Bande, Anil K. Pillai, Lawrence S. Blaszkowsky, Suvranu Ganguli, Muhammad S. Beg, and Sanjeeva P. Kalva. 2014. “Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer.” Frontiers in Oncology 4 (1): 120. doi:10.3389/fonc.2014.00120. http://dx.doi.org/10.3389/fonc.2014.00120.
Research Data
Abstract
Liver metastases from colorectal cancer (CRC) result in substantial morbidity and mortality. The primary treatment is systemic chemotherapy, and in selected patients, surgical resection; however, for patients who are not surgical candidates and/or fail systemic chemotherapy, liver-directed therapies are increasingly being utilized. Yttrium-90 (Y-90) microsphere therapy, also known as selective internal radiation therapy (SIRT) or radioembolization, has proven to be effective in terms of extending time to progression of disease and also providing survival benefit. This review focuses on the use of Y-90 microsphere therapy in the treatment of liver metastases from CRC, including a comprehensive review of published clinical trials and prospective studies conducted thus far. We review the methodology, outcomes, and side effects of Y-90 microsphere therapy for metastatic CRC.
Description
Other Available Sources
Keywords
Review Article, colorectal cancer, liver metastases, radioembolization, Yttrium-90 microspheres, Y-90 therapy, selective internal radiation therapy
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service